Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?

Thumbnail Image

Files

Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants.pdf (154.54 KB)

Date

2024-03-27

Publisher

AME Publishing Company

Authors

Full item page

URI

https://hdl.handle.net/10361/29833

Citation

Homaira N. Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants? Transl Pediatr 2024;13(3):525-529. doi: 10.21037/tp-23-534

Abstract

Keywords

Infants, Monoclonal antibody, Nirsevimab, Respiratory syncytial virus (RSV), Respiratory syncytial virus

LC Subject Headings

Respiratory syncytial virus., Children--Diseases., Infants--Diseases.

Description

Publisher Link

https://tp.amegroups.org/article/view/122378/html

DOI

10.21037/tp-23-534

Department

BRAC James P Grant School of Public Health

Type

Article

Collections

Scholarly Indexed Publications